Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-20 |
2024-03 |
0 |
-2 |
N/A |
N/A |
2024-03-28 |
2023-12 |
0 |
-5 |
N/A |
N/A |
2023-11-13 |
2023-09 |
0 |
-4 |
N/A |
N/A |
2023-08-11 |
2023-06 |
0 |
-2 |
N/A |
N/A |
2023-05-10 |
2023-03 |
0 |
-8 |
N/A |
N/A |
2023-04-04 |
2022-12 |
0 |
-150 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-06 |
Aegis Capital |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-01-05 |
MERZOUKI ABDERRAZZAK |
Chief Operating Officer |
23.34M |
Stock Award(Grant) |
2022-11-29 |
SEBAALY CAMILLE |
Chief Financial Officer |
174.47K |
Purchase |
2021-01-05 |
SLILATY STEVE N |
Chief Executive Officer |
23.34M |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Armistice Capital, LLC |
2.19M |
1.08M |
0.42% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
286.10K |
141.48K |
0.06% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Fund |
286.10K |
141.48K |
0.06% |
Split |
Date |
1 : 100 |
2024-04-17 |
1 : 200 |
2022-02-09 |
1 : 20 |
2020-04-06 |
1 : 20 |
2019-02-01 |